医学
不利影响
肿瘤科
内科学
化疗
荟萃分析
肉瘤
毒性
药品
放射治疗
临床试验
干扰素
疾病
进行性疾病
完全响应
安全概况
细胞毒性T细胞
药理学
系统回顾
外科
疾病控制
皮肤病科
科学网
随机对照试验
梅德林
副作用(计算机科学)
总体生存率
作者
Francisco Cézar Aquino de Moraes,Michele Kreuz,Pedro Henrique de Souza Wagner,Nayara Rozalem Moretti,Ana Luíza Rocha Soares Menegat,Brenda Luana Rocha Soares Menegat,Gustavo Tadeu Freitas Uchôa Matheus,Emanuele Rocha da Silva,Rommel Mário Rodríguez Burbano
标识
DOI:10.1097/cji.0000000000000593
摘要
ABSTRACT: Kaposi Sarcoma (KS) is an angioproliferative tumor induced by human gammaherpesvirus 8 (HHV-8). For years, cytotoxic chemotherapy was the primary treatment for advanced KS, despite high toxicity and limited efficacy. Immunotherapy, particularly PD-1/PD-L1 inhibitors, has emerged as a promising option with antitumor activity and a favorable safety profile. We conducted a meta-analysis to evaluate its efficacy and safety in KS. A systematic search in Medline, Embase, Cochrane Library, and Web of Science identified single-arm trials on PD-1/PD-L1 inhibitors in KS. Outcomes were expressed as proportions with 95% CIs, heterogeneity assessed using I ², and significance set at P <0.05. Analyses were performed in RStudio 4.4.1. Five studies with 91 patients were included. Prior treatments included chemotherapy (35.0%), radiotherapy (22.3%), and interferon (9.2%). The pooled objective response rate (ORR) was 61% (95% CI: 49-72; I ²=16%), with 17% achieving complete response (CR) (95% CI: 8-31; I ²=0%), and the disease control rate (DCR) was 91% (95% CI: 81-96; I ²=0%). The most frequent adverse events (AEs) were pruritus (42%; 95% CI: 16-73; I ²=74%), fatigue (27%; 95% CI: 8-60; I ²=67%), and arthralgia (14%; 95% CI: 5-37; I ²=60%). This meta-analysis supports the antitumor activity of PD-1/PD-L1 inhibitors in KS. Despite high AE rates, most were clinically manageable.
科研通智能强力驱动
Strongly Powered by AbleSci AI